GeneOne Life Science, Inc. (KRX:011000)
South Korea
· Delayed Price · Currency is KRW 2,040.00
-5.00 (-0.24%)
At close: Apr 16, 2025, 3:30 PM KST
GeneOne Life Science Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 35,720 | 40,203 | 48,718 | 38,700 | 41,503 | Upgrade
|
| Other Revenue | 0 | 0 | - | -0 | - | Upgrade
|
| Revenue | 35,720 | 40,203 | 48,718 | 38,700 | 41,503 | Upgrade
|
| Revenue Growth (YoY) | -11.15% | -17.48% | 25.89% | -6.75% | 0.63% | Upgrade
|
| Cost of Revenue | 46,687 | 48,088 | 39,541 | 30,058 | 30,211 | Upgrade
|
| Gross Profit | -10,967 | -7,885 | 9,177 | 8,642 | 11,292 | Upgrade
|
| Selling, General & Admin | 20,804 | 26,627 | 30,867 | 21,498 | 19,651 | Upgrade
|
| Research & Development | 3,556 | 7,043 | 12,147 | 11,441 | 8,396 | Upgrade
|
| Other Operating Expenses | 503.5 | 432.8 | 295.42 | 223.23 | 160.42 | Upgrade
|
| Operating Expenses | 32,072 | 40,483 | 49,376 | 36,170 | 29,821 | Upgrade
|
| Operating Income | -43,039 | -48,368 | -40,199 | -27,527 | -18,529 | Upgrade
|
| Interest Expense | -2,156 | -1,180 | -7,309 | -4,455 | -628.5 | Upgrade
|
| Interest & Investment Income | 125.18 | 518.68 | 6,216 | 1,538 | 561.22 | Upgrade
|
| Currency Exchange Gain (Loss) | -248.79 | 107.21 | 278.95 | 4,361 | -2,424 | Upgrade
|
| Other Non Operating Income (Expenses) | -3,433 | 3,569 | 2,958 | 9,638 | 2,791 | Upgrade
|
| EBT Excluding Unusual Items | -48,751 | -45,353 | -38,056 | -16,445 | -18,230 | Upgrade
|
| Gain (Loss) on Sale of Investments | -4.25 | 4.25 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 2.82 | 3.4 | 1.31 | -106.93 | 3.24 | Upgrade
|
| Asset Writedown | - | -32,309 | - | - | - | Upgrade
|
| Other Unusual Items | - | - | - | 1,018 | - | Upgrade
|
| Pretax Income | -48,753 | -77,655 | -38,054 | -15,534 | -18,226 | Upgrade
|
| Income Tax Expense | -216.19 | 113.45 | 95.79 | 353.75 | 421.99 | Upgrade
|
| Net Income | -48,537 | -77,768 | -38,150 | -15,888 | -18,648 | Upgrade
|
| Net Income to Common | -48,537 | -77,768 | -38,150 | -15,888 | -18,648 | Upgrade
|
| Shares Outstanding (Basic) | 79 | 78 | 77 | 74 | 60 | Upgrade
|
| Shares Outstanding (Diluted) | 79 | 78 | 77 | 74 | 60 | Upgrade
|
| Shares Change (YoY) | 2.20% | 0.34% | 4.37% | 22.98% | 88.03% | Upgrade
|
| EPS (Basic) | -610.85 | -1000.23 | -492.35 | -214.00 | -308.90 | Upgrade
|
| EPS (Diluted) | -611.00 | -1000.23 | -492.35 | -214.00 | -309.00 | Upgrade
|
| Free Cash Flow | -19,356 | -27,345 | -69,419 | -87,291 | -32,069 | Upgrade
|
| Free Cash Flow Per Share | -243.60 | -351.70 | -895.90 | -1175.77 | -531.20 | Upgrade
|
| Gross Margin | -30.70% | -19.61% | 18.84% | 22.33% | 27.21% | Upgrade
|
| Operating Margin | -120.49% | -120.31% | -82.51% | -71.13% | -44.65% | Upgrade
|
| Profit Margin | -135.88% | -193.44% | -78.31% | -41.05% | -44.93% | Upgrade
|
| Free Cash Flow Margin | -54.19% | -68.02% | -142.49% | -225.56% | -77.27% | Upgrade
|
| EBITDA | -25,078 | -35,592 | -34,776 | -22,877 | -14,508 | Upgrade
|
| EBITDA Margin | -70.21% | -88.53% | -71.38% | -59.11% | -34.96% | Upgrade
|
| D&A For EBITDA | 17,961 | 12,776 | 5,424 | 4,650 | 4,021 | Upgrade
|
| EBIT | -43,039 | -48,368 | -40,199 | -27,527 | -18,529 | Upgrade
|
| EBIT Margin | -120.49% | -120.31% | -82.51% | -71.13% | -44.65% | Upgrade
|
| Advertising Expenses | 381.32 | 196.96 | 341.71 | 194.45 | 168.08 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.